NCT03673670View on ClinicalTrials.gov

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions

COPD

Interventions

DRUG

RPL554 Suspension

A PDE3/4 inhibitor

DRUG

Placebo

A placebo solution

DRUG

Tiotropium/olodaterol (Respimat)

An anticholinergic/β-agonist combination medication

Trial Locations (4)

29615

Allied Biomedical Research Holdings, d/b/a Vitalink Research, Greenville

32789

Clinical Site Partners, LLC, Winter Park

W1G8HU

Respiratory Clinical Trials LTD,, London

M23 9QZ

Medicines Evaluation Unit, Manchester

All Listed Sponsors

lead

Verona Pharma plc

INDUSTRY

NCT03673670 - Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD | Biotech Hunter | Biotech Hunter